160,028 Shares in Bristol-Myers Squibb (NYSE:BMY) Purchased by Greystone Financial Group LLC

Greystone Financial Group LLC purchased a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 160,028 shares of the biopharmaceutical company's stock, valued at approximately $9,760,000. Bristol-Myers Squibb makes up 1.8% of Greystone Financial Group LLC's holdings, making the stock its 23rd largest holding.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at about $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $26,000. Fairway Wealth LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $28,000. Transce3nd LLC acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $28,000. Finally, Global Wealth Strategies & Associates lifted its position in shares of Bristol-Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 0.3%

BMY traded up $0.16 during trading hours on Wednesday, hitting $50.13. 10,973,765 shares of the company's stock were exchanged, compared to its average volume of 13,029,986. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The stock's 50-day moving average is $48.87 and its two-hundred day moving average is $54.88. The stock has a market cap of $102.01 billion, a price-to-earnings ratio of -11.34, a PEG ratio of 2.07 and a beta of 0.38. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter last year, the company posted ($4.40) earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

BMY has been the topic of a number of research reports. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Cantor Fitzgerald restated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. UBS Group cut their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Jefferies Financial Group cut their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.